• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

    5/17/24 6:25:14 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRKR alert in real time by email
    SC 13D/A 1 nea16-marker_18847.htm NEW ENTERPRISE ASSOCIATES 16, L.P. / MARKER THERAPEUTICS, INC. -- SCHEDULE 13D/A(#2) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Marker Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    57055L206

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600

    Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    May 15, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 57055L206

    13D Page 2 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 57055L206

    13D Page 3 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

     

     CUSIP No. 57055L206

    13D Page 4 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 16 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

     

      

      CUSIP No. 57055L206

    13D Page 5 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L206

    13D Page 6 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Ali Behbahani

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L206

    13D Page 7 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Carmen Chang

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 57055L206

    13D Page 8 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L206

    13D Page 9 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

        1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

         1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 57055L206

    13D Page 10 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 57055L206

    13D Page 11 of 20 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Paul Walker

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    1,071,428 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    1,071,428 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,071,428 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    12.0%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 57055L206

    13D Page 12 of 20 Pages    

     

    Item 1.  Security and Issuer.

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on October 25, 2018, and Amendment No. 1 thereto filed on March 26, 2021, relating to the common stock, $0.001 par value (the “Common Stock”), of Marker Therapeutics, Inc. (the “Issuer”) having its principal executive office at 9350 Kirby Drive, Suite 300, Houston, Texas 77054.

     

    Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

    This Amendment No. 2 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding and the Warrant Expiration.

     

     

    Item 2.  Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 16, L.P. (“NEA 16”), NEA Partners 16, L.P. (“NEA Partners 16”), which is the sole general partner of NEA 16; and NEA 16 GP, LLC (“NEA 16 LLC” and, together with NEA Partners 16, the “Control Entities”), which is the sole general partner of NEA Partners 16; and

     

    (b) Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Scott D. Sandell (“Sandell”) and Paul Walker (“Walker”) (together, the “Managers”), Joshua Makower (“Makower”) and Peter W. Sonsini (“Sonsini”). The Managers are the managers of NEA 16 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 16, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Behbahani, Chang, Makhzoumi, and Walker is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of NEA 16 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 16 is to act as the sole general partner of NEA 16. The principal business of NEA 16 LLC is to act as the sole general partner of NEA Partners 16. The principal business of each of the Managers is to manage the Control Entities, NEA 16 and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 16 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 16 and NEA Partners 16 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

     

    CUSIP No. 57055L206

    13D Page 13 of 20 Pages    

     

     

     

    Item 3.  Source and Amount of Funds or Other Consideration

    Not applicable.

     

     

    Item 4.  Purpose of Transaction.

    Not applicable.

     

      

    Item 5.  Interest in Securities of the Issuer.

    (a)The amounts of Common Stock reported herein reflect a 1-for-10 reverse stock split effected by the Issuer on January 27, 2023 (the “Reverse Stock Split”). Prior to October 17, 2023 (the “Warrant Expiration Date”), NEA 16 held 375,000 warrants to purchase shares of Common Stock, exercisable immediately, at an exercise price of $50.00 per share with a five-year term (the “NEA 16 Warrants”). On the Warrant Expiration Date, the right of NEA 16 to exercise the NEA 16 Warrants expired by the terms of the applicable warrants and such right was not exercised by the NEA 16, in whole or in part, prior to such expiration (the “Warrant Expiration”).

    Following the Reverse Stock Split and the Warrant Expiration, NEA 16 is the record owner of 1,071,428 shares of Common Stock (the “NEA 16 Shares”). As the general partner of NEA 16, NEA Partners 16 may be deemed to own beneficially the NEA 16 Shares. As the sole general partner of NEA Partners 16, NEA 16 LLC may be deemed to own beneficially the NEA 16 Shares. As members of NEA 16 LLC, each of the Managers may be deemed to own beneficially the NEA 16 Shares.

    Each Reporting Person disclaims beneficial ownership of the NEA 16 Shares other than those shares which such person owns of record.

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on 8,919,095 shares of Common Stock reported by the Issuer to be outstanding as of May 6, 2024 on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 15, 2024. 

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)

    Except as set forth in Item 3 above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

     

    (d)

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)

    Each of Makower and Sonsini has ceased to own beneficially five percent or more of the Issuer’s Common Stock as a result of ceasing to be a manager of NEA 16 LLC.

     

     

    Item 6.  Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

    Item 7.  Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

    Exhibit 3 – Power of Attorney on behalf of Joshua Makower regarding filings under the Securities Exchange Act of 1934, as amended. 

     

     

    CUSIP No. 57055L206

    13D Page 14 of 20 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 17th day of May, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad H. Makhzoumi

     Managing Partner and Co-Chief Executive Officer  

     

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad H. Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

      

     

      

    NEA 16 GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad H. Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

    CUSIP No. 57055L206

    13D Page 15 of 20 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker 

     

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Amendment No. 2 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2 and Exhibit 3.

     

     

     

     
     

     

    CUSIP No. 57055L206

    13D Page 16 of 20 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Marker Therapeutics, Inc.

     

    EXECUTED this 17th day of May, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad H. Makhzoumi

     Managing Partner and Co-Chief Executive Officer  

     

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad H. Makhzoumi

     Managing Partner and Co-Chief Executive Officer

      

     

      

    NEA 16 GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad H. Makhzoumi

    Managing Partner and Co-Chief Executive Officer

     

     

     

     

     

     

     

    CUSIP No. 57055L206

    13D Page 17 of 20 Pages    

     

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker 

     

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

     

    This Agreement relating to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Powers of Attorney, copies of which are attached hereto as Exhibit 2 and Exhibit 3.

     

     

     

    CUSIP No. 57055L206

    13D Page 18 of 20 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact. 

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

     

     

     

     

    CUSIP No. 57055L206

    13D Page 19 of 20 Pages    

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

     

     

    CUSIP No. 57055L206

    13D Page 20 of 20 Pages    

     

    EXHIBIT 3

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager or former general partner, director, officer or manager of any New Enterprise Associates partnership, corporation or limited liability company, solely with respect to the following entities: Black Diamond Therapeutics, Inc., Inventiva S.A., Marker Therapeutics, Monte Rosa Therapeutics, Inc., and Reneo Pharmaceuticals, Inc. (the “Covered Entities”), pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney will last for the duration of the outstanding filing obligations related to the undersigned and NEA Management Company, LLC, and its affiliates. Upon the removal of the undersigned from all outstanding Form 3, 4, and 5, Schedule 13D and 13G or any other similarly related obligatory filings related to the Covered Entities, the power provided herein shall be revoked. 

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 2nd day of May, 2024.

     

     

    /s/ Joshua Makower  
    Joshua Makower  
       

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $MRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRKR

    DatePrice TargetRatingAnalyst
    3/5/2025$8.00Buy
    Canaccord Genuity
    2/17/2022$3.00 → $1.00Buy → Neutral
    Roth Capital
    More analyst ratings

    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

      HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Onc

      4/1/25 8:00:14 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

      Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs Approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for "neldaleucel" as nonproprietary name for MT-601 Strategic financing to support cli

      3/31/25 8:45:00 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Elms Steve

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:20:34 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Knobil Katharine

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:19:38 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Eansor Norman David

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:18:35 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Financials

    Live finance-specific insights

    See more
    • Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

      Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In

      2/16/22 4:30:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

      HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68

      2/8/22 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

      HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.   "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu

      11/10/21 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/26/24 4:01:17 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/23/24 4:40:48 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

      CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

      8/28/24 8:00:00 AM ET
      $KRRO
      $MRKR
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

      Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St

      3/25/24 5:45:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    SEC Filings

    See more
    • Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/20/25 8:32:01 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Marker Therapeutics Inc.

      10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/15/25 5:00:50 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marker Therapeutics Inc.

      SCHEDULE 13G/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/15/25 4:13:40 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/17/24 6:25:14 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/26/21 10:38:04 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/15/21 4:45:13 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Marker International with a new price target

      Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

      3/5/25 7:37:58 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics downgraded by Roth Capital with a new price target

      Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      2/17/22 6:14:24 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Marker Therapeutics with a new price target

      Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00

      3/25/21 6:18:22 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care